In vitro anti-HIV-1 activity of salicylidene acylhydrazide compounds

International Journal of Antimicrobial Agents

Volumn 40, Issue 4, 2012, Pages 354-360

  Forthal, Donald N ^a   Phan, Tran B ^a   Slepenkin, Anatoly V ^b   Landucci, Gary ^a   Chu, Hencelyn ^b   Elofsson, Mikael ^c   Peterson, Ellena ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UMEÅ UNIVERSITY   (Sweden)

Author keywords

HIV; Iron chelation; Microbicide; Salicylidene acylhydrazides

Indexed keywords

FERROUS ION; HYDRAZIDE DERIVATIVE; INP 0149; INP 0161; INP 0341; INP 0400; N' (2 HYDROXY 1 NAPHTHALENYLMETHYLENE) 4 CHLOROBENZHYDRAZIDE; N' (4 DIETHYLAMINO 2 HYDROXYBENZYLIDENE) 2,4 DIHYDROXYBENZHYDRAZIDE; N' (4 DIETHYLAMINO 2 HYDROXYBENZYLIDENE)ISONICOTINIC ACID HYDRAZIDE; N' (5 CHLORO 2 HYDROXY 3 METHYLBENZYLIDENE) 2,4 DIHYDROXYBENZHYDRAZIDE; SALICYLIDENE ACYLHYDRAZIDE DERIVATIVE; UNCLASSIFIED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CLADISTICS; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG STRUCTURE; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IN VITRO STUDY; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SPERM; VAGINA DISCHARGE; VIRUS DNA CELL DNA INTERACTION; VIRUS INHIBITION; VIRUS REPLICATION;

ANTI-HIV AGENTS; BODILY SECRETIONS; CELLS, CULTURED; FEMALE; HIV-1; HUMANS; HYDRAZINES; INHIBITORY CONCENTRATION 50; MALE; MICROBIAL SENSITIVITY TESTS; SCHIFF BASES; VIRUS REPLICATION;

EID: 84866029593     PISSN: 09248579     EISSN: 18727913     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2012.05.023     Document Type: Article

References (19)

1. Q. Abdool Karim, S.S. Abdool Karim, J.A. Frohlich, A.C. Grobler, C. Baxter, and L.E. Mansoor Effectiveness and safety of tenofovir gel, an antiretroviral microbicide, for the prevention of HIV infection in women Science 329 2010 1168 1174
2. R. Nordfelth, A.M. Kauppi, H.A. Norberg, H. Wolf-Watz, and M. Elofsson Small-molecule inhibitors specifically targeting type III secretion Infect Immun 73 2005 3104 3114
3. L. Bailey, A. Gylfe, C. Sundin, S. Muschiol, M. Elofsson, and P. Nordstrom Small molecule inhibitors of type III secretion in Yersinia block the Chlamydia pneumoniae infection cycle FEBS Lett 581 2007 587 595
4. A. Slepenkin, P.A. Enquist, U. Hagglund, L.M. de la Maza, M. Elofsson, and E.M. Peterson Reversal of the antichlamydial activity of putative type III secretion inhibitors by iron Infect Immun 75 2007 3478 3489
5. H. Chu, A. Slepenkin, M. Elofsson, P. Keyser, L.M. de la Maza, and E.M. Peterson Candidate vaginal microbicides with activity against Chlamydia trachomatis and Neisseria gonorrhoeae Int J Antimicrob Agents 36 2010 145 150
6. A. Slepenkin, H. Chu, M. Elofsson, P. Keyser, and E.M. Peterson Protection of mice from a Chlamydia trachomatis vaginal infection using a salicylidene acylhydrazide, a potential microbicide J Infect Dis 204 2011 1313 1320
7. Z. Debebe, T. Ammosova, M. Jerebtsova, J. Kurantsin-Mills, X. Niu, and S. Charles Iron chelators ICL670 and 311 inhibit HIV-1 transcription Virology 367 2007 324 333
8. Z. Debebe, T. Ammosova, D. Breuer, D.B. Lovejoy, D.S. Kalinowski, and P.K. Karla Iron chelators of the di-2-pyridylketone thiosemicarbazone and 2-benzoylpyridine thiosemicarbazone series inhibit HIV-1 transcription: identification of novel cellular targets - iron, cyclin-dependent kinase (CDK) 2, and CDK9 Mol Pharmacol 79 2011 185 196
9. H.N. Traore, and D. Meyer The effect of iron overload on in vitro HIV-1 infection J Clin Virol 31 Suppl. 1 2004 S92 S98
10. N.A. Georgiou, T. van der Bruggen, M. Oudshoorn, H.S. Nottet, J.J. Marx, and B.S. van Asbeck Inhibition of human immunodeficiency virus type 1 replication in human mononuclear blood cells by the iron chelators deferoxamine, deferiprone, and bleomycin J Infect Dis 181 2000 484 490
11. M. Hoque, H.M. Hanauske-Abel, P. Palumbo, D. Saxena, D. D'Alliessi Gandolfi, and M.H. Park Inhibition of HIV-1 gene expression by ciclopirox and deferiprone, drugs that prevent hypusination of eukaryotic initiation factor 5A Retrovirology 6 2009 90
12. B.S. van Asbeck, N.A. Georgiou, T. van der Bruggen, M. Oudshoorn, H.S. Nottet, and J.J. Marx Anti-HIV effect of iron chelators: different mechanisms involved J Clin Virol 20 2001 141 147
13. M.K. Dahlgren, C.E. Zetterstrom, S. Gylfe, A. Linusson, and M. Elofsson Statistical molecular design of a focused salicylidene acylhydrazide library and multivariate QSAR of inhibition of type III secretion in the Gram-negative bacterium Yersinia Bioorg Med Chem 18 2010 2686 2703
14. D.H. Owen, and D.F. Katz A vaginal fluid simulant Contraception 59 1999 91 95
15. D.H. Owen, and D.F. Katz A review of the physical and chemical properties of human semen and the formulation of a semen simulant J Androl 26 2005 459 469
16. V.R. Gordeuk, J.R. Delanghe, M.R. Langlois, and J.R. Boelaert Iron status and the outcome of HIV infection: an overview J Clin Virol 20 2001 111 115
17. R. Rawat, J.H. Humphrey, R. Ntozini, K. Mutasa, P.J. Iliff, and R.J. Stoltzfus Elevated iron stores are associated with HIV disease severity and mortality among postpartum women in Zimbabwe Public Health Nutr 12 2009 1321 1329
18. J.M. McDermid, A. Jaye, M.F. Schim van der Loeff, J. Todd, C. Bates, and S. Austin Elevated iron status strongly predicts mortality in West African adults with HIV infection J Acquir Immune Defic Syndr 46 2007 498 507
19. Y. Jin, Z. Tan, M. He, B. Tian, S. Tang, and I. Hewlett SAR and molecular mechanism study of novel acylhydrazone compounds targeting HIV-1 CA Bioorg Med Chem 18 2010 2135 2140